Dupilumab-Associated Mycosis Fungoides with a CD8+ Immunophenotype
Dupilumab is a humanized IgG4 monoclonal-antibody that is approved by the United States Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older. In recent years, several case studies have associated the unmasking or progre...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Dermatopathology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2296-3529/9/4/45 |